2Seventy Competitors

Delisted . USA . 
Stock . 2Seventy Bio
TSVTDelisted Stock  USD 5.00  0.00  0.00%   
2Seventy Bio competes with Alaunos Therapeutics, and Lifecore Biomedical; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing 2Seventy Bio competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of 2Seventy Bio to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

2Seventy Bio vs Catabasis Pharmaceuticals Correlation

Moving together with 2Seventy Stock

  0.68BKRKY Bank RakyatPairCorr

Moving against 2Seventy Stock

  0.7PBCRY Bank Central AsiaPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of 2Seventy Bio's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
5.005.005.00
Details
Intrinsic
Valuation
LowRealHigh
3.713.715.50
Details
Naive
Forecast
LowNextHigh
4.494.494.49
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
5.005.005.00
Details

2Seventy Bio Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between 2Seventy Bio and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of 2Seventy and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of 2Seventy Bio does not affect the price movement of the other competitor.

High positive correlations

CRGX
+ 0.78
SCPH
THRD
+ 0.75
INZY
SCPH
+ 0.7
INZY
TCRT
+ 0.6
SLRN
CRGX
+ 0.57
INZY
SCPH
+ 0.5
THRD
  

High negative correlations

TCRT
- 0.77
THRD
TCRT
- 0.74
INZY
SLRN
- 0.68
INZY
SLRN
- 0.54
THRD
CRGX
- 0.31
SLRN
TCRT
- 0.25
SCPH

Risk-Adjusted Indicators

There is a big difference between 2Seventy Stock performing well and 2Seventy Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze 2Seventy Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
INZY  8.04  3.53  0.61 (2.02) 3.27 
(11.66)
 10.42 
(7.26)
 179.17 
THRD  0.29  0.05  0.05  0.66  0.00 
(0.51)
 0.58 
(0.38)
 3.41 
SCPH  2.39  0.62  0.17 (0.88) 2.34 
(2.79)
 7.28 
(4.75)
 17.14 
SLRN  3.22  0.16  0.03  0.23  4.22 
(3.86)
 5.85 
(5.84)
 35.54 
MACK  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CRGX  1.04  0.11  0.07  0.36  0.98 
(1.57)
 4.17 
(2.01)
 8.42 
SPPI  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
TCRT  4.12  0.14  0.01 (0.21) 5.34 
(4.25)
 9.82 
(9.52)
 24.31 
LFCR  1.81 (0.02) 0.00  0.11  0.00 
 0.00 
 2.80 
(4.30)
 16.31 
CATB  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 

2Seventy Bio Competitive Analysis

The better you understand 2Seventy Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, 2Seventy Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across 2Seventy Bio's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TSVT INZY THRD SCPH SLRN CRGX TCRT LFCR
 0.00 
 5.00 
2Seventy
 0.00 
 4.00 
Inozyme
 0.00 
 5.38 
Third
 0.18 
 5.67 
Scpharmaceuticals
 0.00 
 2.27 
ACELYRIN,
 0.00 
 4.47 
CARGO
 0.90 
 3.35 
Alaunos
 3.32 
 6.99 
Lifecore
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Very steady
Very steady
Very steady
Very risky
Somewhat reliable
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Hazard
Hazard
Hazard
Hazard
Hazard
Hazard
High
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Hold
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Not Rated
Not Rated
Not Rated
Not Rated
Strong Sell
Strong Sell
Current Ratio
3.88 X
14.54 X
23.59 X
3.72 X
N/A
N/A
2.29 X
N/A
Net Asset
479.51 M
123.18 M
294.61 M
107.52 M
491.14 M
414.05 M
2.75 M
239.34 M
Profit Margin
(0.08) %
N/A
N/A
(1.84) %
N/A
N/A
N/A
(0.30) %
EBITDA
(115.43 M)
(104.03 M)
(45.42 M)
(77.43 M)
(247.8 M)
(160.43 M)
(4.68 M)
(8.81 M)
Operating Margin
(0.11) %
N/A
N/A
(0.89) %
N/A
N/A
(678.83) %
(0.1) %
Current Valuation
335.53 M
220.43 M
(25.82 M)
315.46 M
(175.46 M)
(35.8 M)
1.35 M
387.98 M
Price To Book
1.24 X
8.12 X
0.89 X
28.45 X
0.56 X
0.91 X
2.64 X
192.10 X
Retained Earnings
(568.46 M)
(387.95 M)
(159.69 M)
(366.49 M)
(736.95 M)
(312.65 M)
(920.45 M)
(205.24 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
1.05
2.29
2.13
0.3
1.09
N/A
-1.25
0.59
Number Of Employees
65
67
31
162
83
167
1
406
Shares Outstanding
53.23 M
64.56 M
45.13 M
53.68 M
100.95 M
48.36 M
2.23 M
37.47 M
Cash Flow From Operations
(85 M)
(91.91 M)
(34.5 M)
(70.54 M)
(303.92 M)
(139.74 M)
(4.97 M)
(206 K)
Total Debt
243.72 M
46.87 M
3.21 M
52.69 M
6.27 M
29.43 M
692 K
130.82 M
Return On Equity
-0.0194
-1.42
-0.2
-9.34
-0.51
-0.66
-1.46
-0.76
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.0749
-0.48
-0.15
-0.57
-0.3
-0.26
-0.7
-0.0304
Number Of Shares Shorted
2.59 M
3.38 M
1.42 M
811.77 K
3.57 M
3.04 M
38.21 K
2.73 M
Book Value Per Share
4.08 X
0.49 X
6.06 X
(0.40) X
4.04 X
5.11 X
1.27 X
0.04 X
Current Liabilities
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
479.51 M
123.18 M
294.61 M
107.52 M
491.14 M
414.05 M
2.75 M
239.34 M
Debt To Equity
0.73 %
0.02 %
7.81 %
0.32 %
N/A
N/A
0.69 %
N/A
Short Ratio
2.44 X
0.78 X
6.95 X
0.36 X
3.80 X
1.08 X
2.39 X
19.05 X
Target Price
5.0
4.0
3.0
5.68
8.0
7.0
1.75
9.25
Shares Owned By Institutions
82.40 %
94.29 %
80.11 %
80.35 %
91.97 %
99.28 %
6.36 %
76.37 %
Market Capitalization
266.14 M
258.25 M
242.79 M
304.36 M
229.17 M
216.19 M
7.41 M
270.88 M
Price To Earnings To Growth
N/A
(0.06) X
N/A
N/A
N/A
N/A
N/A
3.51 X
Price To Earning
N/A
N/A
23.13 X
N/A
N/A
N/A
N/A
N/A
Price To Sales
5.50 X
N/A
N/A
6.09 X
N/A
N/A
1,235 X
2.10 X
Net Income
(57.25 M)
(102.02 M)
(45.47 M)
(85.15 M)
(248.23 M)
(167.5 M)
(4.68 M)
(38.72 M)
Earnings Per Share
(0.08) X
(1.68) X
(1.24) X
(1.81) X
(2.69) X
(4.62) X
(2.30) X
(1.27) X
Shares Owned By Insiders
6.44 %
1.26 %
9.11 %
5.97 %
7.15 %
0.62 %
4.37 %
1.90 %
Revenue
37.86 M
N/A
N/A
36.33 M
N/A
N/A
10 K
128.87 M
Working Capital
147.16 M
86.78 M
283.43 M
90.97 M
454.41 M
319.99 M
2.06 M
55.5 M
Cash And Equivalents
357.93 M
151.48 M
112.73 M
55.85 M
N/A
N/A
60.01 M
N/A
Cash Per Share
9.45 X
3.77 X
25.53 X
2.04 X
N/A
N/A
0.28 X
N/A
Gross Profit
(13.24 M)
N/A
N/A
34.21 M
N/A
N/A
(910 K)
40.3 M
Day Typical Price
5.0
4.0
5.38
5.68
2.27
4.47
3.29
6.96
Accumulation Distribution
N/A
N/A
N/A
0.0105
N/A
N/A
1069.57
3762.77
Market Facilitation Index
N/A
N/A
N/A
0.06
N/A
N/A
0.0
0.0
Daily Balance Of Power
0.0
0.0
0.0
(0.17)
0.0
0.0
0.1111
(0.96)
Period Momentum Indicator
N/A
N/A
N/A
(0.01)
N/A
N/A
0.03
(0.24)
Rate Of Daily Change
1.0
1.0
1.0
1.0
1.0
1.0
1.01
0.97
Day Median Price
5.0
4.0
5.38
5.68
2.27
4.47
3.26
6.95
Price Action Indicator
N/A
N/A
N/A
(0.01)
N/A
N/A
0.11
(0.07)
Relative Strength Index
88.51
82.73
51.38
76.83
36.01
1.41
7.86
21.56
Coefficient Of Variation
672.08
658.01
735.23
598.35
2466.17
1145.34
4224.07
(9,064)
Mean Deviation
3.27
8.04
0.2949
2.39
3.22
1.04
4.12
1.81
Jensen Alpha
1.39
3.53
0.0513
0.6194
0.1563
0.1126
0.1407
(0.02)
Total Risk Alpha
0.9633
2.35
0.0313
0.4178
(0.05)
0.0496
(0.15)
(0.16)
Sortino Ratio
0.4835
0.6066
0.0474
0.1744
0.0316
0.0712
0.0148
N/A
Downside Variance
8.41
31.94
0.137
10.22
22.36
1.54
31.59
N/A
Standard Deviation
9.74
22.86
0.4733
3.62
4.84
1.55
5.49
2.49
Kurtosis
57.31
54.43
17.8
2.75
4.98
2.98
0.0497
3.57
Potential Upside
6.69
10.42
0.5825
7.28
5.85
4.17
9.82
2.8
Treynor Ratio
1.04
(2.02)
0.6567
(0.88)
0.2284
0.363
(0.21)
0.1088
Maximum Drawdown
78.0
179.17
3.41
17.14
35.54
8.42
24.31
16.31
Variance
94.84
522.81
0.224
13.08
23.45
2.4
30.18
6.18
Market Risk Adjusted Performance
1.05
(2.01)
0.6667
(0.87)
0.2384
0.373
(0.20)
0.1188
Risk Adjusted Performance
0.1214
0.1242
0.0966
0.1339
0.039
0.071
0.0265
(0)
Skewness
7.33
7.1
3.18
0.8455
0.5832
1.27
0.143
0.7367
Semi Deviation
1.06
3.27
0.0
2.34
4.22
0.9768
5.34
N/A
Information Ratio
0.144
0.1499
0.0371
0.1542
0.0309
0.0571
0.0152
(0.03)
Value At Risk
(3.47)
(7.26)
(0.38)
(4.75)
(5.84)
(2.01)
(9.52)
(4.30)
Expected Short fall
(5.03)
(11.66)
(0.51)
(2.79)
(3.86)
(1.57)
(4.25)
N/A
Downside Deviation
2.9
5.65
0.3701
3.2
4.73
1.24
5.62
N/A
Semi Variance
1.12
10.7
(0)
5.48
17.81
0.9541
28.49
N/A

2Seventy Bio Competition Performance Charts

Five steps to successful analysis of 2Seventy Bio Competition

2Seventy Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by 2Seventy Bio in relation to its competition. 2Seventy Bio's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of 2Seventy Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact 2Seventy Bio's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to 2Seventy Bio, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your 2Seventy Bio position

In addition to having 2Seventy Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run RUB Crypto Assets Thematic Idea Now

RUB Crypto Assets
RUB Crypto Assets Theme
An experimental p2p digital currency that is accepted by many vendors in Russian Ruble. The RUB Crypto Assets theme has 0 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize RUB Crypto Assets Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Consideration for investing in 2Seventy Stock

If you are still planning to invest in 2Seventy Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the 2Seventy Bio's history and understand the potential risks before investing.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bonds Directory
Find actively traded corporate debentures issued by US companies
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY